Dysgerminoma — Trials

Dysgerminoma — Trials · CancerIndex

Clinical trials

Registered studies

4 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: Memorial Sloan Kettering Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00042952	Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer	terminated	Phase 2	32	National Cancer Institute (NCI)NIH	1	Jan 17, 2013	clinicaltrials

Data updated 23 days agoSource updated Jan 17, 2013source: clinicaltrials